FDA Clears New Diagnostic Test for Advanced Prostate Cancer Treatment

The U.S. FDA has granted approval for Roche's Ventana PTEN RxDx Assay, a novel diagnostic test for prostate cancer. This test helps identify patients with metastatic, hormone-sensitive prostate cancer who could benefit from a specific combination therapy. The approval marks a step forward in personalized treatment approaches for prostate cancer.